Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults Patients With Alopecia Areata

Conditions

Diseases of the Integumentary System | Genetics - Adult

Phase II

What is the purpose of this trial?

Brief Summary:

A randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata

  • Trial with
    Concert Pharmaceuticals
  • Start Date
    03/19/2019
  • End Date
    12/30/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Rebecca Chawarski

  • Last Updated
    04/08/2019
  • Study HIC
    #2000025038